New Review of the Clinical Characteristics and Blood Glucose Data from Cellnovo System Users Using Data Collected from the Cellnovo Online Platform - touchENDOCRINOLOGY
LONDON, April 24, 2018 /PRNewswire/ --
Olivia Hautier-Suply, Yasmin Friedmann, Julian Shapley; European Endocrinology, 2018;14(1):Epub ahead of print
(Logo: http://mma.prnewswire.com/media/515766/Touch_Medical_Logo.jpg )
To be published in European Endocrinology, the peer-reviewed journal from touchENDOCRINOLOGY, Olivia Hautier-Suply et al, discuss technological advances have led to innovative insulin delivery systems for patients with type 1 diabetes mellitus. In particular, the combination of miniature engineering and software algorithms contained in continuous subcutaneous insulin infusion (CSII) system pumps provide the user and the healthcare practitioner with an opportunity to review and adjust blood glucose (BG) levels according to system feedback, and to modify or programme their regimen according to their needs. While CSII pumps record a number of data parameters such as BG level, carbohydrate intake, activity and insulin delivered, these data are generally 'locked in' and can only be accessed by uploading to a cloud-based system, thus information is not contemporaneous. The Cellnovo Diabetes Management System (Cellnovo, Bridgend, UK) allows data to be transmitted securely and wirelessly in real time to a secure server, which is then retrieved by an online platform, the Cellnovo Online platform, enabling continuous access by the user and by clinicians. In this article, the authors describe a retrospective review of the patient data automatically uploaded to the Cellnovo Online platform. Baseline clinical and demographic characteristics collected at the start of pump therapy are shown for all patients, and BG data from a sub-cohort of patients who have been using the system for at least 6 months and who take and record an average of three BG level tests per day are presented to demonstrate glycaemic data over time.
The full peer-reviewed, open-access article is available here:
Disclosure: Olivia Hautier-Suply, Yasmin Friedmann and Julian Shapley are employees of Cellnovo Ltd. The publication of this article was supported by Cellnovo Ltd.
touchENDOCRINOLOGY (a division of Touch Medical Media) publishesEuropean Endocrinology, a peer-reviewed, open access, bi-annual journal specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of endocrinology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals.
Touch Medical Media is a trading name of Touch Digital Media Limited, a private limited company registered in England and Wales at The White House Mill Road, Goring, Reading, England, RG8 9DD with registered number 08197142.
For inquires please contact:
Nicola Cartridge - Editorial Director
editor@touchmedicalmedia.com
T: +44-(0)-207-193-3186
Leading the Debate on the Advances in Healthcare
Share this article